Posted by Michael Wonder on 25 Sep 2018
Synergy Pharmaceuticals strengthens coverage for Trulance (plecanatide) with key new market access wins
24 September 2018 - Synergy Pharmaceuticals today announced several new formulary wins improving Trulance 2018 and 2019 coverage status across major U.S. Commercial, Medicare Part D and Managed Medicaid plans.
New 2018 & 2019 Trulance Formulary Wins
2018 Express Scripts Medicare Part D Formulary
Express Scripts is now offering all lives covered under its largest Medicare Part D Formulary, Value Formulary, unrestricted access to TRULANCE, effective September 15, 2018.
2018 OptumRx Formularies
OptumRx will soon be offering TRULANCE as an unrestricted preferred agent for their Commercial, Managed Medicaid and Medicare Part D clients, effective October 1, 2018.
Synergy is continuing to work with OptumRx and their largest client, UnitedHealthcare, to improve TRULANCE coverage for both Commercial and Medicare Part D members.
2018 and 2019 UnitedHealthcare Community Plan
Starting October 1, 2018, TRULANCE coverage status will improve from not covered to an unrestricted, preferred agent on the UnitedHealthcare Managed Medicaid formulary.
Effective January 1, 2019, TRULANCE will be one of two unrestricted, preferred agents on the UnitedHealthcare Managed Medicaid formulary.
2019 Express Scripts Commercial Formularies
Express Scripts will add TRULANCE as an unrestricted preferred agent on its 2019 High Performance Formulary, effective January 1, 2019. This coverage win builds on the announcement last month that Express Scripts will add TRULANCE to its 2019 National Preferred Formulary, effective January 1, 2019.
Synergy is continuing to work with Express Scripts and their regional health plan clients to further expand coverage for TRULANCE starting in 2019.
